Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.38 |
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942450 | 0.73 | ATM (0.53) | ATMSLC6A4HTR1AALDH1A1TSHR | |
| SCHEMBL17602837 | 0.71 | TACR3 (0.51) | ATMFAAHLMNASIGMAR1ALDH1A1 | |
| SCHEMBL4826474 | 0.71 | LMNA (0.51) | FAAHLMNAGAAALDH1A1CCR3 | |
| SCHEMBL15668032 | 0.71 | TACR3 (0.51) | ATMFAAHLMNASIGMAR1ALDH1A1 | |
| SCHEMBL18970534 | 0.71 | ATM (0.47) | ATMSLC6A4HTR1ASIGMAR1ALDH1A1 | |
| Fumaric Acid SCHEMBL6388246 | 0.70 | HRH1 (0.49) | SLC6A4 | |
| Fumaric Acid SCHEMBL6388259 | 0.70 | HRH1 (0.49) | SLC6A4 | |
| SCHEMBL9253235 | 0.70 | CCR3 (0.43) | LMNAGAAALDH1A1KDM4ECCR3 | |
| SCHEMBL16334656 | 0.69 | ATM (0.50) | ATMSLC6A4HTR1AALDH1A1KDM4E | |
| SCHEMBL16334148 | 0.69 | ATM (0.50) | ATMSLC6A4HTR1AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1598068-A1 | Antipsychotic heterocycle compounds | Bristol-Myers Squibb Company (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1242072-A4 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6476051-B2 | FOR THERAPY OF PSYCHOSIS, ACUTE MANIA, MILD ANXIETY STATES, OR DEPRESSION IN COMBINATION WITH PSYCHOTIC EPISODES | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| EP-1242072-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020072611-A1 | Antipsychotic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| EP-1146871-A4 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1146871-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001043740-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6225324-B1 | POTENT INHIBITION OF 5-HT REUPTAKE; 1,3-DISUBSTITUTED PYRROLIDINE, 1,4-DISUBSTITUTED PIPERIDINE, OR 1,4-DISUBSTITUTED HEXAHYDROAZEPINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2000044376-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072611-A1 | Antipsychotic heterocycle compounds | HTR2C, DRD2, HTR1A | ATM 3986/4885SLC6A4 60/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.